216 Chapter 9 Table 1. Baseline characteristics of study participantsa b ULDCT (n = 1208) CXR (n = 1210) Mean age (±SD), y 59.0 (18.1) 59.0 (18.6) Female sex 613 (50.7) 587 (48.5) Comorbidity Charlson Comorbidity Index (IQR)d 3.0 (1.0-5.0) 3.0 (1.0-5.0) Immunocompromised 285 (23.6) 246 (20.3) Malignancyc 229 (19.0) 222 (18.3) Diabetesc 230 (19.0) 245 (20.2) Pulmonary disease Chronic obstructive pulmonary diseasec 175 (14.5) 179 (14.8) Asthma 141 (11.7) 109 (9.0) Interstitial lung disease 29 (2.4) 28 (2.3) Cystic fibrosis 14 (1.2) 14 (1.2) Cardiac disease Myocardial infarctionc 159 (13.2) 169 (14.0) Chronic cardiac failurec 98 (8.1) 98 (8.1) Neurological diseasec 140 (11.6) 149 (12.3) Kidney diseasec 104 (8.6) 119 (9.8) Thromboembolic disease 92 (7.6) 107 (8.8) Presenting symptoms Dyspnoea 663 (54.9) 695 (57.4) Cough 679 (56.2) 631 (52.1) Fever 514 (42.5) 468 (38.7) Thoracic pain 442 (36.6) 460 (38.0) Sputum production 378 (31.3) 354 (29.3) Haemoptysis 54 (4.5) 41 (3.4) Confusion 50 (4.1) 41 (3.4) Clinical question on radiology request form Pneumonia 837 (69.3) 822 (67.9) Pulmonary congestion 76 (6.3) 114 (9.4) Bronchitis 108 (8.9) 57 (4.7) Pneumothorax 36 (3.0) 69 (5.7) Pleural effusion 35 (2.9) 46 (3.8) Pulmonary tumour 10 (0.8) 10 (0.8) Atelectasis 4 (0.3) 3 (0.3) Pulmonary metastases 4 (0.3) 3 (0.2) Other 90 (7.5) (6.5)
RkJQdWJsaXNoZXIy MTk4NDMw